| 1 |
UNAIDS. UNAIDS report 2017[EB/OL]．
URL
|
| 2 |
Patel R, Moore T, Cooper V, et al. An obervational study of comorbidity and healthcare utilization among HIV positive aged 50 years and over[J]. Int J STD AIDS, 2016, 27(8): 628-637.
|
| 3 |
Bhavna H, Emma DJ, Amthony B, et al. Insights into respiratory disease through bioinformatics[J]. Respir, 2018, 23(12): 1117-1126.
|
| 4 |
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China(the China Pulmonary Health [CPH]study): a nationalcross-sectionalstudy[J]. Lancet, 2018, 391(10131): 1706-1717.
|
| 5 |
任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
|
| 6 |
North CM, MacNaughton P, Lai PS, et al. Personal carbon monoxide exposure, respiratory symptoms, and the potentially modifying roles of sex and HIV infection in rural Uganda: a cohort study[J]. Environ Health, 2019, 18(1): 73.
|
| 7 |
Katerina B, Ken MK, Joshua V, et al. Chronic obstructive pulmonary disease in HIV[J]. Expert Rev Respir, 2021, 15(1): 71-87.
|
| 8 |
Alex K, Adaeze CW, Tasmia N, et al. Chronic obstructive pulmonary disease prevalence and associated factors in a setting of well-controlled HIV, A cross-sectional study[J]. COPD, 2020, 17(3): 297-305.
|
| 9 |
Asiki G, Reniers G, Newton R, et al. Adult life expectancy trends in the era of antiretroviral treatment in rural Uganda(1991-2012)[J]. AIDS, 2016, 30(3): 487-493.
|
| 10 |
North CM, Allen JG, Okello S, et al. HIV infection, pulmonary tuberculosis, and COPD in rural uganda: A cross-sectional study[J]. Lung, 2018, 196(1): 49-57.
|
| 11 |
Cribbs SK, Crothers K, Morris A. Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation[J]. Physiol Rev, 2020, 100(2): 603-632.
|
| 12 |
Crothers K, McGinnis K, Kleerup E, et al. HIV infection is associated with reducedpulmonary diffusing capacity[J]. J Acquir Immune Defic Syndr, 2013, 64(3): 271-288.
|
| 13 |
Mendez R, Banerjee S, Bhattacharya SK, et al. Lung inflammation and disease: A perspective on microbial homeostasis and metabolism[J]. IUBMB Life, 2019, 71(2): 152-165.
|
| 14 |
Yang L, Dunlap DG, Qin S, et al. Alterations in oral microbiota in HIV are related to decreased pulmonary function[J]. Am J Respir Crit Care Med, 2020, 201(4): 445-457.
|
| 15 |
张知远，金海珍，余欣颐. 慢阻肺急性加重期患者外周血T细胞中PD-1/PD-L1的表达及意义[J]. 中华全科医学，2020, 18(3): 86-89+93.
|
| 16 |
Hunegnaw R, Mushtaq Z, Enyindah-Asonye G, et al. Alveolar macrophage dysfunction and increased PD-1 expression during chronic SIV infection of rhesus macaques[J]. Front Immunol, 2019, 10: 1537.
|
| 17 |
Neff CP, Logue EC, Siebert J, et al. Loss of anti-inflammatory alveolar macrophages associates with lung inflammation in untreated HIV infection[J]. J Immunol, 2020, 248: 15.
|
| 18 |
Neff CP, Chain JL, MaWhinney S, et al. Lymphocytic alveolitis is associated with the accumulation of functionally impaired HIV-specific T cells in the lung of antiretroviral therapy-naive subjects[J]. Am J Respir Crit Care Med, 2015, 191(4): 464-473.
|
| 19 |
Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity，and mortality in treated HIV infection[J]. J Infect Dis, 2016, 214: 44-50.
|
| 20 |
Costiniuk CT, Salahuddin S, Farnos O, et al. HIV persistence in mucosal CD4+ T cells within the lungs of adults receiving long-term suppressive antiretroviral therapy[J]. AIDS, 2018, 32(16): 2279-2289.
|
| 21 |
Cribbs SK, Lennox J, Caliendo AM, et al. Healthy HIV-1-infected individuals on highly active antiretroviral therapy harbor HIV-1 in their alveolar macrophages[J]. AIDS Res Hum Retroviruses, 2015, 31(1): 64-70.
|
| 22 |
Leader JK, Crothers K, Huang L, et al. Risk factors associated with quantitative evidence of lung emphysema and fibrosis in an HIV-infected cohort[J]. J Acquir Immune Defic Syndr, 2016, 71(4): 420-427.
|
| 23 |
Pezzuto A, Carico E. Effectiveness of smoking cessation in smokers with COPD and nocturnal oxygen desaturation: functional analysis[J]. Clin Respir J, 2020, 14(1): 29-34.
|
| 24 |
Le Mao R, Tromeur C, Paleiron N, et al. Effect of early initiation of varenicline on smoking cessation in COPD patients admitted for exacerbation：the save randomized clinical trial[J]. COPD, 2020, 17(1): 7-14.
|
| 25 |
Perez MF, Atuegwu NC, Mead EL, et al. Adult E-cigarettes use associated with a self-reported diagnosis of COPD[J]. Int J Environ Res Public Heal, 2019, 16(20): 3938.
|
| 26 |
Nguyen HQ, Moy ML, Liu IA, et al. Effect of physical activity coaching on acute care and survival among patients with chronic obstructive pulmonary disease：a pragmatic randomized clinical trial[J]. JAMA Netw Open, 2019, 2(8): e199657.
|
| 27 |
Kunisaki KM, Niewoehner DE, Collins G, et al. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial[J]. Lancet Respir Med, 2016, 4(12): 980-989.
|
| 28 |
Kunisaki KM, Baker JV, Collins G, et al. Lung function decline in early HIV infection: impact of antiretroviral drug timing and drug regimen[J]. Am J Respir Crit Care Med, 2020, 201(6): 739-741.
|
| 29 |
Hoy JF, Grund B, Roediger M, et al. Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START bone mineral density substudy, a randomized trial[J]. J Bone Miner Res, 2017, 32(9): 1945-1955.
|
| 30 |
Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label，phase 3, non-inferiority study[J]. Lancet Infect Dis, 2016, 16(1): 43-52.
|
| 31 |
Global strategy for the diagnosis，management and prevention of chronic obstructive pulmonary disease 2021 report[OL]．(2020-11-17)[2020-12-15]．
URL
|
| 32 |
Mingjin Y, Yuejun D, Hong C, et al. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials[J]. Int Immunopharmacol, 2019, 77(12): 105950.
|
| 33 |
Janson C, Lisspers K, Johansson G, et al. Osteoporosis and fracture risk associated with ICS use among Swedish COPD patients: the ARCTIC study[J]. Eur Respir J, 2020, 57(2): 2000515.
|
| 34 |
Dobler CC, Morrow AS, Beuschel B, et al. Pharmacologic therapies in patients with exacerbation of chronic obstructive pulmonary disease: A systematic review with meta-analysis[J]. Ann Intern Med, 2020, 172(6): 413-422.
|